Artiva (ARTV) Q2 Loss Widens 19.7%
Artiva Biotherapeutics (NASDAQ:ARTV), a clinical-stage biotechnology company pioneering allogeneic natural killer (NK) cell therapies for autoimmune diseases, released its financial results for the second quarter on August 6, 2025. The earnings showed a net loss per share of $(0.87), which was wider than the consensus estimate of $(0.81). As expected at its current development phase, the company reported no revenue. Research and development costs increased sharply to support expanded clinical activity, and cash reserves declined. The quarter highlighted ongoing operational momentum in the clinic but also the persistence of significant financial losses.
Source: Analyst estimates for the quarter provided by FactSet.
Artiva Biotherapeutics (NASDAQ:ARTV) develops “off-the-shelf” allogeneic NK cell therapies—immune treatments made from donor-derived cells that can be manufactured in advance and held in inventory. Its main product family is AlloNK, designed to deplete B-cells, which drive many autoimmune conditions, and to enhance antibody-dependent cell killing.
Source Fool.com
